{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T03:00:59.335390+00:00","company":{"ticker":"TARS","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc."},"pagination":{"limit":100,"returned":10,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"00971625ff66d9ea9a2b4d511bb84b87f7751685","cik":1819790,"ticker":"TARS","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":"$(0.16)","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$7.0 million","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-06","result_type":"reported_results","revenue_text":"$145.4 million"},"claim":"Tarsus Pharmaceuticals, Inc. reported first quarter ended March 31, 2026 results: revenue $145.4 million, net income $7.0 million, EPS $(0.16). Guidance reaffirmed.","evidence_excerpt":"• Product sales, net: were $145.4 million compared to $78.3 million for the same period in 2025, driven by higher volume and improvements in the gross-to-net discount.\n• License fees and collaboration revenue: were $16.7 million related to a $15.0 million regulatory milestone achieved under the China Out-License and $1.7 million of required China withholding tax associated with this milestone. The milestone payment was recorded on a gross basis, which increased license fees and collaboration revenue by $1.7 million, with an equal offsetting amount recorded as foreign tax expense within provision for income taxes. There were no license fees and collaboration revenue in the same period in 2025.\n• Cost of sales: were $9.4 million compared to $5.2 million for the same period in 2025, due to manufacturing costs related to XDEMVY, the royalty Tarsus pays on net product sales, and amortization expense for the milestone payments made to our licensor, which is being amortized over its remaining","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001819790-26-000037","anchor_url":"https://secwatch.observer/filing/0001819790-26-000037#claim-00971625ff66d9ea9a2b4d511bb84b87f7751685","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000037/0001819790-26-000037-index.htm"},{"fact_type":"executive_change","fact_key":"6dd978b173","cik":1819790,"ticker":"TARS","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2025-01-17T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-01-17","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Rosemary Crane resigned as Director at Tarsus Pharmaceuticals, Inc..","evidence_excerpt":"On January 15, 2025, Rosemary Crane, a member of the Board of Directors (the “Board”) of Tarsus Pharmaceuticals, Inc. (the “Company”) notified the Company of her resignation as a member of the Board and any committees of the Board, effective January 17, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001819790-25-000003","anchor_url":"https://secwatch.observer/filing/0001819790-25-000003#claim-6dd978b173","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000003/0001819790-25-000003-index.htm"},{"fact_type":"executive_change","fact_key":"53cc6378e1","cik":1819790,"ticker":"TARS","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2024-11-05T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-11-04","interim":false,"role":"Member of the Board of Directors","role_category":"director","successor_name":null,"successor_named":false},"claim":"Elizabeth Yeu resigned as Member of the Board of Directors at Tarsus Pharmaceuticals, Inc..","evidence_excerpt":"In connection with the appointment, on November 1, 2024, Dr. Yeu resigned as a member of the Company's board of directors (the \"Board\") and from the committees of the Board on which she served, each effective as of the Effective Date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001819790-24-000119","anchor_url":"https://secwatch.observer/filing/0001819790-24-000119#claim-53cc6378e1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000119/0001819790-24-000119-index.htm"},{"fact_type":"executive_change","fact_key":"0f0200862c","cik":1819790,"ticker":"TARS","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2024-11-05T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-11-04","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Elizabeth Yeu was appointed as Chief Medical Officer at Tarsus Pharmaceuticals, Inc..","evidence_excerpt":"On November 5, 2024, Tarsus Pharmaceuticals, Inc. (the \"Company\") announced the appointment of Elizabeth Yeu, M.D. as the Company's Chief Medical Officer, effective as of November 4, 2024 (the \"Effective Date\").","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001819790-24-000119","anchor_url":"https://secwatch.observer/filing/0001819790-24-000119#claim-0f0200862c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000119/0001819790-24-000119-index.htm"},{"fact_type":"earnings_release","fact_key":"6f4fd4638919d9630b43be4dfca74ca1ba070da6","cik":1819790,"ticker":"TARS","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2024-05-08T23:59:59+00:00","payload":{"eps_text":"$(1.01)","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$35.7 million","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-08","result_type":"reported_results","revenue_text":"$27.6 million"},"claim":"Tarsus Pharmaceuticals, Inc. reported first quarter ended March 31, 2024 results: revenue $27.6 million, net income $35.7 million, EPS $(1.01).","evidence_excerpt":"million at the close, providing approximately $40 million net after the repayment of the previous facility First Quarter 2024 Financial Results •    First quarter revenues were $27.6 million, driven primarily by $24.7 million in net product sales, and $2.9 million in license fees and collaboration revenue. •    Cost of sales were $1.7 million, due to manufacturing","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001819790-24-000062","anchor_url":"https://secwatch.observer/filing/0001819790-24-000062#claim-6f4fd4638919d9630b43be4dfca74ca1ba070da6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000062/0001819790-24-000062-index.htm"},{"fact_type":"debt_financing","fact_key":"4d34f7687c492ac3cbc45c887cbd60fc243c7b17","cik":1819790,"ticker":"TARS","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2024-04-23T23:59:59+00:00","payload":{"counterparty":"funds managed by Pharmakon Advisors LP, BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, as lenders, and BioPharma Credit PLC, as collateral agent","effective_date":"2024-04-19","event":"incurrence","instrument_type":"term_loan","interest_rate_text":"90-day average secured overnight financing rate (\"SOFR\"), plus a margin of 6.75%","item_codes_triggered":["2.03"],"maturity_text":"April 19, 2029","principal_text":"$75 million"},"claim":"Tarsus Pharmaceuticals, Inc. incurred term loan of $75 million with funds managed by Pharmakon Advisors LP, BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, as lenders, and BioPharma Credit PLC, as collateral agent at 90-day average secured overnight financing rate (\"SOFR\"), plus a margin of 6.75% maturing April 19, 2029.","evidence_excerpt":"The Loan Agreement provides for an initial term loan in the principal amount of $75 million (the \"Tranche A Loan\") which was funded on April 19, 2024 (the \"Tranche A Closing Date\").","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001819790-24-000050","anchor_url":"https://secwatch.observer/filing/0001819790-24-000050#claim-4d34f7687c492ac3cbc45c887cbd60fc243c7b17","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000050/0001819790-24-000050-index.htm"},{"fact_type":"material_agreement","fact_key":"593594c7d75ac30f43d51f1f32459df4d3c76215","cik":1819790,"ticker":"TARS","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2024-04-23T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Loan Agreement","agreement_type":"credit_facility","counterparty":"funds managed by Pharmakon Advisors LP, BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, as lenders, and BioPharma Credit PLC, as collateral agent","effective_date":"2024-04-19","item_codes_triggered":["1.01"],"value_text":"initial term loan in the principal amount of $75 million"},"claim":"Tarsus Pharmaceuticals, Inc. entered into Loan Agreement with funds managed by Pharmakon Advisors LP, BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, as lenders, and BioPharma Credit PLC, as collateral agent valued at initial term loan in the principal amount of $75 million (effective 2024-04-19).","evidence_excerpt":"On April 19, 2024, Tarsus Pharmaceuticals, Inc., a Delaware corporation (the “Company”) entered into an agreement with funds managed by Pharmakon Advisors LP, BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, as lenders, and BioPharma Credit PLC, as collateral agent for the lenders, and the guarantors party to such agreement (the “Loan Agreement”). The Loan Agreement provides for an initial term loan in the principal amount of $75 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001819790-24-000050","anchor_url":"https://secwatch.observer/filing/0001819790-24-000050#claim-593594c7d75ac30f43d51f1f32459df4d3c76215","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000050/0001819790-24-000050-index.htm"},{"fact_type":"material_agreement","fact_key":"e56b64fc145b5ef62fdb71943eb1ef7ef40fed14","cik":1819790,"ticker":"TARS","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2024-03-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"Goldman Sachs & Co. LLC, BofA Securities, Inc. and Guggenheim Securities, LLC","effective_date":"2024-02-29","item_codes_triggered":["1.01"],"value_text":"expected to be approximately $93.7 million"},"claim":"Tarsus Pharmaceuticals, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, BofA Securities, Inc. and Guggenheim Securities, LLC valued at expected to be approximately $93.7 million (effective 2024-02-29).","evidence_excerpt":"On February 29, 2024, Tarsus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, BofA Securities, Inc. and Guggenheim Securities, LLC, acting as representatives of the underwriters named in the Underwriting Agreement (the “Underwriters”), relating to the sale of 2,812,500 shares of the Company’s common stock, par value $0.0001 per share, and, in lieu of common stock to a certain investor, pre-funded warrants to purchase 312,500 shares of its common stock (the “Offering”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-24-056209","anchor_url":"https://secwatch.observer/filing/0001193125-24-056209#claim-e56b64fc145b5ef62fdb71943eb1ef7ef40fed14","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1819790/000119312524056209/0001193125-24-056209-index.htm"},{"fact_type":"earnings_release","fact_key":"a3259cb18c7d7de4a30ac22474432d641c2e44ec","cik":1819790,"ticker":"TARS","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2024-02-27T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"Full Year 2023","report_date":"2024-02-27","result_type":"reported_results","revenue_text":"$17.4 million"},"claim":"Tarsus Pharmaceuticals, Inc. reported Full Year 2023 results: revenue $17.4 million.","evidence_excerpt":"Total revenues were $17.4 million, driven primarily by $14.7 million in XDEMVY net product sales, representing approximately four months of sales following the launch in late August.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001819790-24-000015","anchor_url":"https://secwatch.observer/filing/0001819790-24-000015#claim-a3259cb18c7d7de4a30ac22474432d641c2e44ec","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000015/0001819790-24-000015-index.htm"},{"fact_type":"earnings_release","fact_key":"e982cfef05912e7ea956924bbef0949d8df0810b","cik":1819790,"ticker":"TARS","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2024-02-27T23:59:59+00:00","payload":{"eps_text":"$(1.31)","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$(41.9 million)","period_text":"Fourth Quarter 2023","report_date":"2024-02-27","result_type":"reported_results","revenue_text":"$13.1 million"},"claim":"Tarsus Pharmaceuticals, Inc. reported Fourth Quarter 2023 results: revenue $13.1 million, net income $(41.9 million), EPS $(1.31).","evidence_excerpt":"Recent Business Achievements Launched XDEMVY ® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis and generated fourth quarter net product sales of $13.1 million, and $14.7 million in the first four months since launch Delivered more than 17,400 bottles of XDEMVY to patients Continued pipeline execution – reported positive","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001819790-24-000015","anchor_url":"https://secwatch.observer/filing/0001819790-24-000015#claim-e982cfef05912e7ea956924bbef0949d8df0810b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000015/0001819790-24-000015-index.htm"}]}